RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.
* Pemvidutide: 2.4 mg SC once weekly
* Placebo: Placebo SC once weekly

开始日期2025-07-01

申办/合作机构

Altimmune, Inc.

NCT06987513

/ Recruiting临床2期

RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms:
* Pemvidutide: 2.4 mg SC once weekly
* Placebo: Placebo SC once weekly

开始日期2025-05-15

申办/合作机构

Altimmune, Inc.

NCT05989711

/ Active, not recruiting临床2期

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

开始日期2023-07-27

申办/合作机构

Altimmune, Inc.

100 项与 Pemvidutide 相关的临床结果

登录后查看更多信息

100 项与 Pemvidutide 相关的转化医学

登录后查看更多信息

100 项与 Pemvidutide 相关的专利（医药）

登录后查看更多信息

项与 Pemvidutide 相关的文献（医药）

2025-05-01·PEPTIDES

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

Review

作者: Flatt, Peter R ; Bailey, Clifford J ; Conlon, J Michael

Recent studies with peptide-based incretin therapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and the dual agonist tirzepatide that engages receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials and 'real-world' studies have confirmed the marked glucose-lowering and weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young and elderly individuals with and without diabetes and/or overweight or obesity. Recent studies have also confirmed protections against the development and progression of cardiovascular and renal diseases that are additive to the benefits conferred by improved control of blood glucose and body weight. Emerging evidence suggests that incretin therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea and possibly degenerative bone disorders and cognitive decline. New incretin-based peptide therapies in development include a long-acting glucagon receptor agonist (LY3324954), dual GLP-1/glucagon receptor agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon receptor agonists (retatrutide, efocipegtrutide), a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), a unimolecular GLP-1/amylin receptor dual agonist (amycretin), and a GIP receptor antibody with GLP-1 receptor agonism (MariTide). The creation of multi-targeting incretin-based synthetic peptides provides opportunities for improved management of type 2 diabetes and obesity as well as new therapeutic approaches to an expanding list of associated co-morbidities. The aim of the review is to acquaint the reader with developments in the field from 2023 to the present (February 2025).

2025-02-01·Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego

Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL – 2024

Review

作者: Khaitovych, Mykola V. ; Pinsky, Leonid L. ; Ryzhova, Irina P. ; Golubovska, Olga A.

Aim: To systematize and comprehensively analyze scientific sources and studies on metabolic-associated steatotic liver disease (MASLD) based on materials from the European Congress of the European Association for the Study of the Liver (EASL – 2024). Materials and Methods: This paper analyzes the current scientific research on the prevalence, pathogenesis, diagnostic methods, prognosis, and pharmacotherapy of MASLD presented at the EASL 2024 Congress. The following methods were used in the preparation of the work: a systematic approach and bibliosemantic analysis. Conclusions: Studies on the pathogenesis of MASLD progression confirm the significant role of insulin resistance and hyperinsulinemia in increasing hepatocyte cytolysis activity, raising the concentration of cytokeratin CK-18, HbA1c, low-density lipoproteins, triglycerides, and the severity of fibrosis (FIB-4). EASL 2024 studies evaluated the diagnostic efficiency of non-invasive methods for assessing steatosis and liver fibrosis severity in MASLD (FIB-4, FibroScan®, Enhanced Liver Fibrosis (ELF), Vibration Controlled Transient Elastography (VCTE), LiverPRO, etc.). Due to the high prevalence of steatotic liver disease, comorbidities such as chronic viral hepatitis C, autoimmune hepatitis, and alcoholic liver disease – contributing to liver fibrosis progression and hepatocellular carcinoma – are significant. Promising drugs for MASLD treatment include resmethyrom, fibroblast growth factor 21 analogs (including pegosafermin), and pemvidutide, a long-acting, balanced GLP-1/glucagon dual receptor agonist.

2025-01-01·JOURNAL OF HEPATOLOGY

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

Article

作者: Browne, Sarah K ; Harrison, Stephen A ; Gutierrez, Julio A ; Roberts, M Scot ; Suschak, John J ; Harris, M Scott ; Yang, Jay ; Tomah, Shaheen

BACKGROUND & AIMS:

This was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

METHODS:

Patients with a BMI ≥28.0 kg/m² and LFC ≥10% by magnetic resonance imaging-proton density fat fraction were randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo administered subcutaneously once weekly for 12 weeks. Participants were stratified according to a diagnosis of type 2 diabetes mellitus. The primary efficacy endpoint was relative reduction (%) from baseline in LFC after 12 weeks of treatment.

RESULTS:

Ninety-four patients were randomized and dosed. Median baseline BMI and LFC across the study population were 36.2 kg/m² and 20.6%; 29% of patients had type 2 diabetes mellitus. At week 12, relative reductions in LFC from baseline were 46.6% (95% CI -63.7 to -29.6), 68.5% (95% CI -84.4 to -52.5), and 57.1% (95% CI -76.1 to -38.1) for the pemvidutide 1.2 mg, 1.8 mg, and 2.4 mg groups, respectively, vs. 4.4% (95% CI -20.2 to 11.3) for the placebo group (p <0.001 vs. placebo, all treatment groups), with 94.4% and 72.2% of patients achieving 30% and 50% reductions in LFC and 55.6% achieving normalization (≤5% LFC) at the 1.8 mg dose. Maximal responses for weight loss (-4.3%; p <0.001), alanine aminotransferase (-13.8 IU/L; p = 0.029), and corrected cT1 (-75.9 ms; p = 0.002) were all observed at the 1.8 mg dose. Pemvidutide was well-tolerated at all doses with no severe or serious adverse events.

CONCLUSIONS:

In patients with MASLD, weekly pemvidutide treatment yielded significant reductions in LFC, markers of hepatic inflammation, and body weight compared to placebo.

IMPACT AND IMPLICATIONS:

Metabolic dysfunction-associated steatotic liver disease, and its progressive form steatohepatitis, are strongly associated with overweight/obesity and it is believed that the excess liver fat associated with obesity is an important driver of these diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists elicit weight loss through centrally and peripherally mediated effects on appetite. Unlike GLP-1R agonists, glucagon receptor agonists act directly on the liver to stimulate fatty acid oxidation and inhibit lipogenesis, potentially providing a more potent mechanism for liver fat content reduction than weight loss alone. This study demonstrated the ability of once-weekly treatment with pemvidutide, a dual GLP-1R/glucagon receptor agonist, to significantly reduce liver fat content, hepatic inflammatory activity, and body weight, suggesting that pemvidutide may be an effective treatment for both metabolic dysfunction-associated steatohepatitis and obesity.

CLINICAL TRIAL NUMBER:

NCT05006885.

169

项与 Pemvidutide 相关的新闻（医药）

2025-06-30

·药时空

结果不理想！GLP-1/GCGR双激动剂脂肪肝2b期研究

6月26日（当地时间），Alt immune Inc宣布其GLP-1R和GCGR（1：1）双激动剂Pemvidutide治疗代谢功能障碍相关脂肪性肝炎（MASH）2b期临床研究（IMPACT）顶线结果积极。IMPACT研究（NCT05988711）为一项旨在评估Pemvidutide在非肝硬化的非酒精性脂肪肝炎（NASH）患者中安全性和有效性的随机、双盲、安慰剂对照的多中心2b临床研究。研究主要终点为MASH减退&纤维化未恶化和纤维化改善&MASH未恶化双指标，次要终点包括体重变化和无创纤维化。研究入组212例活检证实的MASH和纤维化F2/3期有/无糖尿病的患者1：2：2随机接受24周每周皮下注射一次Pemvidutide（1.2、1.8mg）或安慰剂治疗。24周研究顶线结果如下：ITT分析，1.2和1.8mg Pemvidutide组分别有59.1%和52.1%患者实现MASH减退&纤维化未恶化，安慰剂组为19.1%（两剂量水平p均＜0.0001）；额外ITT分析，1.2和1.8mg Pemvidutide组分别有31.8%和34.5%患者实现纤维化改善，安慰剂组为25.9%（差异不显著）；补充基于AI分析显示，1.8mg Pemvidutide组患者30.6%获得超60%纤维化改善，安慰剂组为8.2%（p＜0.001）；1.2和1.8mg Pemvidutide组分别有25.8%和24.1%患者实现MASH减退&纤维化改善双指标严格终点，安慰剂组为13.5%（差异不显著）；1.2和1.8mg Pemvidutide组患者体重分别减少5%和6.2%，安慰剂组为1%（p＜0.001），24周轨迹尚未稳定；1.2和1.8mg Pemvidutide组患者肝脏脂肪分别减少58%和62.8%，安慰剂组为16.2%（两剂量p＜0.001）；1.2和1.8mg Pemvidutide组AE导致治疗中断患者比例分别为0%和1.2%，安慰剂组为2.4%。24周为报告药物或心率失常相关SAE；HbA1C无论糖尿病状态变化维持血糖控制。Pemvidutide是一种新型在研基于肽的GLP-1/胰高血糖素双受体（1：1）激动剂。GLP-1和胰高血糖素受体激活被认为模拟了饮食和运动对减肥的互补作用，GLP-1抑制食欲，胰高血糖素增加能量消耗。胰高血糖素还被认为对肝脏脂肪代谢有直接影响，据信这会导致肝脏脂肪和血脂水平的快速降低。识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

临床结果临床2期

2025-06-29

·药时空

Altimmune股价腰斩！Pemvidutide治疗MASH的2期临床喜忧参半

2025年6月26日，Altimmune公司宣布其Pemvidutide治疗代谢功能障碍相关脂肪性肝炎（MASH）的2b期临床试验（IMPACT试验）取得了积极的顶线结果。试验设计- IMPACT试验是一项随机、双盲、安慰剂对照的2b期临床试验，共纳入212名经活检确认的MASH患者，这些患者的肝纤维化程度为F2/F3期，且无论是否患有糖尿病，均被随机分配至每周接受皮下注射1.2mg或1.8mg剂量的Pemvidutide或安慰剂治疗，持续24周。- 该试验的主要终点是在24周时实现MASH缓解且肝纤维化程度无恶化，次要终点包括体重减轻和肝纤维化的非侵入性检测。临床试验结果- MASH缓解：在意向治疗（ITT）分析中，接受Pemvidutide 1.2mg和1.8mg治疗的患者中，分别有59.1%和52.1%实现了MASH缓解且肝纤维化程度无恶化，而安慰剂组的比例仅为19.1%（p<0.0001）。- 肝纤维化改善：在ITT分析中，接受Pemvidutide 1.2mg和1.8mg治疗的患者中，分别有31.8%和34.5%实现了肝纤维化改善且MASH无恶化，而安慰剂组的比例为25.9%（差异无统计学意义）。- 补充AI分析：补充的人工智能（AI）基础分析显示，接受Pemvidutide 1.8mg治疗的患者中，有30.6%实现了肝纤维化程度至少减少60%，而安慰剂组的比例仅为8.2%（p<0.001）。- 体重减轻：在24周时，接受Pemvidutide 1.2mg和1.8mg治疗的患者平均体重分别减轻了5.0%和6.2%，而安慰剂组仅减轻了1.0%（p<0.001）。- 安全性：Pemvidutide表现出良好的安全性和耐受性，因不良事件导致治疗中断的比例在Pemvidutide 1.2mg和1.8mg组分别为0.0%和1.2%，而安慰剂组为2.4%。Altimmune公司计划在2025年第四季度与美国食品药品监督管理局（FDA）举行2期结束会议，并有望迅速推进至3期临床试验。结束语：Pemvidutide作为一种GLP-1/胰高血糖素双受体激动剂24周时达到主要终点MASH缓解且肝纤维化程度无恶化。然而，与安慰剂相比，该药在肝纤维化方面未能显示出统计学上显著的改善，肝纤维化是更具挑战性的终点。而司美格鲁泰（72周）和替尔泊肽（52周）均在肝纤维化改善做出统计差异。这可能是引起投资人不满意的一个重要原因。识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

临床结果临床2期临床3期临床成功

2025-06-28

·药明康德

使六成患者获完全缓解的免疫组合疗法；2-4天快速起效的干眼症多肽疗法…… | TIDES周报

▎药明康德近期，全球多肽和寡核苷酸（TIDES）领域迎来系列进展。Enterome公司基于肿瘤肽的免疫疗法EO2463联用来那度胺和利妥昔单抗治疗惰性非霍奇金淋巴瘤（NHL），在一项2期临床试验中的完全缓解（CR）率达60%。用于治疗代谢功能障碍相关性脂肪性肝炎（MASH）和肥胖症的胰高血糖素样肽-1（GLP-1）/胰高血糖素双重受体激动剂pemvidutide达2b期临床试验主要终点。在研环肽疗法certepetide联合标准化疗治疗转移性胰腺导管腺癌（mPDAC），患者的无进展生存期和客观缓解率（ORR）都获得了有临床意义的改善。本文将节选其中部分重要进展做简单介绍，仅供读者参阅。EO2463：公布2期联合治疗试验的中期数据Enterome公司公布了其基于肿瘤肽的免疫疗法EO2463与来那度胺和利妥昔单抗联用治疗惰性NHL的积极2期临床结果。EO2463由4种模拟B细胞肿瘤相关抗原CD20、CD22、CD37和CD268（BAFF受体）的多肽以及辅助性的UCP2肽组成，能够激活抗肿瘤免疫反应，清除癌变B细胞。此次公布的结果显示，EO2463联合来那度胺和利妥昔单抗治疗后，60%（12/20）的患者达到了CR。该组合疗法在滤泡性淋巴瘤和边缘区淋巴瘤患者中耐受性良好。此外，该研究中观察到的CR率高于历史数据中来那度胺联用利妥昔单抗治疗所预期的水平。Certepetide：公布2b期联合治疗试验数据Lisata Therapeutics公司与澳大利亚胃肠试验组（AGITG）、悉尼大学NHMRC临床试验中心公布了2b期临床试验ASCEND的初步结果。该试验评估了Lisata公司的在研环肽疗法certepetide联合标准治疗化疗用于治疗转移性胰腺导管腺癌患者的效果。Certepetide旨在激活一种肿瘤特异性的转运系统，使与之联合使用的全身性抗癌药物能够更有效地穿透肿瘤并在肿瘤内蓄积。此外，certepetide还被证明可以调节肿瘤微环境，使肿瘤对免疫疗法更加敏感。该研究包括两个队列，队列A的患者在吉西他滨输注结束后、白蛋白紫杉醇输注开始前，静脉推注certepetide 3.2 mg/kg。队列B的患者在队列A治疗方案的基础上，在首次给药4小时后追加一次certepetide或安慰剂。此前公布的队列A的结果显示，患者的总生存期呈现出积极趋势，并且有4例患者达到CR，而安慰剂组未观察到任何CR病例。此次公布的队列B的初步数据显示，certepetide组的6个月无进展生存率为60.8%，安慰剂组为25%；两组的中位无进展生存期分别为7.5个月和4.7个月；ORR分别为45.2%和19%；中位总生存期分别为10.32个月和9.23个月。队列A和队列B的数据比较表明，在标准化疗中加入两剂certepetide（队列B方案）使mPDAC患者的无进展生存期和ORR都获得了有临床意义的改善。Pemvidutide：公布2b期临床试验数据Altimmune公司公布了pemvidutide治疗MASLD的2b期试验的积极结果。Pemvidutide是一种GLP-1/胰高血糖素双重受体激动剂，目前正在开发用于治疗MASH和肥胖症。该研究中，212名经活检证实的MASH和纤维化F2/F3期伴或不伴糖尿病的受试者按1：2：2的比例被随机分配接受pemvidutide（1.2 mg或1.8 mg）或安慰剂，持续24周。此次公布的结果显示，在意向治疗（ITT）人群分析中，试验达到了其主要终点。在24周时，pemvidutide高剂量组患者中有59.1%达到了MASH缓解，且未出现纤维化的恶化；34.5%的受试者出现了纤维化改善，且没有发生MASH的加重。基于人工智能（AI）的补充分析表明，接受pemvidutide治疗24周后，患者的肝纤维化改善具有统计学意义。此外，pemvidutide高剂量组患者在24周时的平均减重幅度达到6.2%，且体重仍在持续下降，尚未出现平台期。安全性方面，pemvidutide表现出潜在“best-in-class”的耐受性，因不良事件而停药的比例低于1%。Vezocolmitide（ST-100）：公布3期临床试验的初步数据Stuart Therapeutics公司公布了其3期临床试验的初步结果，该试验评估了ST-100滴眼液治疗干眼症（DED）的疗效。ST-100是一种胶原模拟肽类药物，其独特机制可通过修复眼部受损的胶原蛋白来恢复眼表稳态，从而减轻DED的影响。此次公布的结果显示，ST-100治疗起效迅速，在治疗2-4天内就能缓解患者的体征和症状。其中，ST-100治疗一周后荧光素染色评分（用于量化眼表上皮细胞损伤程度）的改善幅度超过了现有已批准的DED治疗药物/产品的公开报告数据。该研究结果将有助于指导ST-100的第二项3期研究的设计。Salanersen（BIIB115/ION306）：公布1期临床试验的中期数据渤健（Biogen）公布了其在研反义寡核苷酸（ASO）疗法salanersen（BIIB115/ION306）用于治疗脊髓性肌萎缩症（SMA）的一项1期临床试验的积极结果。Salanersen最初由Ionis Pharmaceuticals发现，渤健之前从Ionis Pharmaceuticals获得了salanersen的全球开发、生产及商业化权利。该药物与渤健已获批的ASO疗法Spinraza（nusinersen）具有相同的作用机制，但在设计上追求更高效力，并有望实现每年仅需一次给药。在此次中期分析中，研究对象为一组既往接受过基因治疗但临床状态仍不理想的SMA患儿。结果显示，无论是40 mg还是80 mg剂量，salanersen均表现出良好的耐受性，并可显著降低神经退行性标志物神经丝轻链（NfL）的水平。在基线NfL浓度较高的患者中，治疗6个月后平均NfL下降幅度达70%，这一效果可持续维持至一年。除了安全性和生物标志物数据外，研究还对部分随访时间达到一年的患儿（n=8，年龄2至12岁）进行了初步临床结局评估，结果同样令人鼓舞。半数患者（4人）达成了此前无法独立完成或需他人协助完成的世界卫生组织（WHO）运动发育里程碑，如独立行走、爬行、站立或坐起。基于这一积极成果，渤健正与监管机构沟通，计划推进salanersen进入注册性临床研究阶段，进一步拓展该公司在SMA治疗领域的布局。BW-40202：1期临床试验完成首例受试者给药舶望制药宣布，其在研小干扰RNA（siRNA）药物BW-40202的1期临床试验已完成首例健康受试者给药，该里程碑在澳大利亚临床研究中心达成。此外，BW-40202已获得中国国家药品监督管理局（NMPA）的IND批准，将在中国临床研究中心同步推进。BW-40202是一种靶向肝脏中补体因子B（CFB）mRNA的siRNA药物，用于治疗补体介导疾病。该药物通过抑制CFB mRNA的表达来降低血清CFB蛋白水平，并抑制补体替代途径（CAP）活性。在临床前研究中，BW-40202表现出优异的纯度和稳定性，能够显著降低血清CFB蛋白水平，有效抑制CAP活性，并具有长效性和良好的安全性。参考资料（可上下滑动查看）[1] RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS. Retrieved June 23, 2025, from https://www.prnewswire.com/news-releases/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions-302487811.html[2] Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet. Retrieved June 20, 2025, from https://www.prnewswire.com/news-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet-302487500.html[3] Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions. Retrieved June 21, 2025, from https://www.businesswire.com/news/home/20250620108098/en/Verdiva-Bio-to-Present-New-Data-Highlighting-Once-Weekly-Potential-of-Its-Investigational-Oral-Obesity-Candidates-at-the-ADA-85th-Scientific-Sessions[4] Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML. Retrieved June 27, 2025, from https://www.globenewswire.com/news-release/2025/06/23/3103112/0/en/Enterome-presents-positive-Phase-2-interim-results-in-relapsed-refractory-indolent-non-Hodgkin-lymphoma-after-EO2463-OncoMimics-immunotherapy-treatment-at-ICML.html[5] Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA. Retrieved June 27, 2025, from https://www.globenewswire.com/news-release/2025/06/20/3102978/0/en/Novo-Nordisk-Higher-dose-of-Wegovy-provided-average-weight-loss-of-21-in-people-with-obesity-with-a-third-achieving-25-or-more-according-to-data-presented-at-ADA.html[6] Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes. Retrieved June 27, 2025, from https://www.prnewswire.com/news-releases/semaglutide-increases-walking-capacity-in-patients-with-peripheral-artery-disease-and-type-2-diabetes-302486241.html[7] Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes. Retrieved June 27, 2025, from https://www.prnewswire.com/news-releases/oral-semaglutide-significantly-improves-cardiovascular-outcomes-in-individuals-with-type-2-diabetes-302487712.html[8] 甘李药业双周GLP-1RA博凡格鲁肽在第85届美国糖尿病协会年会（ADA 2025）公布优异数据. Retrieved June 27, 2025, from https://mp.weixin.qq.com/s/Me2jPwZs4apc8h1oGrMzWg[9] Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results. Retrieved June 25, 2025 from https://investors.biogen.com/news-releases/news-release-details/biogen-advance-investigational-spinal-muscular-atrophy-asset[10] Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions. Retrieved June 25, 2025 from https://www.prnewswire.com/news-releases/innovent-announces-the-phase-3-clinical-study-dreams-1-of-mazdutide-in-china-were-orally-presented-at-ada-85th-scientific-sessions-302489772.html[11] 博瑞医药在ADA2025发布GLP-1/GIP受体激动剂BGM0504II期积极数据及新型Amylin BGM1812临床前成果. Retrieved June 27, 2025, from https://mp.weixin.qq.com/s/a8v46EscZGWt3LaqlYCQ9w[12] Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer. Retrieved June 27, 2025, from https://ir.lisata.com/news-releases/news-release-details/positive-preliminary-cohort-b-results-agitg-led-ascend-trial-be[13] Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH. Retrieved June 27, 2025, from https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-topline-results-impact-phase-2b[14] Stuart Therapeutics Announces Initial Results of Phase III Clinical Trial for ST-100 (Vezocolmitide) Ophthalmic Solution, a Novel Dry Eye Disease Candidate. Retrieved June 27, 2025, from https://www.prnewswire.com/news-releases/stuart-therapeutics-announces-initial-results-of-phase-iii-clinical-trial-for-st-100-vezocolmitide-ophthalmic-solution-a-novel-dry-eye-disease-candidate-302489203.html[15] W. Timothy Garvey, et al., (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The N Engl J Med, DOI: 10.1056/NEJMoa2502081[16] Melanie J. Davies, et al., (2025). Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The N Engl J Med, DOI: 10.1056/NEJMoa2502082[17] 舶望制药治疗补体介导疾病新药BW-40202完成临床I期首例受试者给药. Retrieved June 27, 2025, from https://www.argobiopharma.com/cn/news/113.html免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

免疫疗法临床2期临床结果

100 项与 Pemvidutide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非酒精性脂肪性肝炎	临床3期	美国	Altimmune, Inc.	-
肥胖	临床3期	美国	Altimmune, Inc.	-
酒精性肝疾病	临床2期	美国	Altimmune, Inc.	2025-07-01
酒精性肝疾病	临床2期	波多黎各	Altimmune, Inc.	2025-07-01
酒精使用障碍	临床2期	美国	Altimmune, Inc.	2025-05-15
2型糖尿病	临床1期	美国	Altimmune, Inc.	2021-09-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05292911 (GlobeNewswire) 人工标引	临床2期	肥胖	67	Pemvidutide	遞範淵願餘襯遞觸鏇觸(積獵鑰築夢鏇積鏇襯積) = 遞鹹鹽淵齋顧壓鑰夢壓選鏇窪範遞築夢網齋構 (範糧窪餘選齋築遞遞築 ) 更多	积极	2024-09-10
NCT01625260 (CTgov)	临床1/2期	非肌层浸润性膀胱肿瘤	12	Gemcitabine+ALT-801 (0.06 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)	製膚蓋範顧襯齋餘遞窪 = 壓鬱壓築範齋選衊構齋範窪襯鏇夢願構淵獵夢 (憲糧觸廠鏇夢獵夢憲製, 齋壓鏇製憲醖築齋齋範 ~ 繭繭觸壓壓餘鏇夢齋艱) 更多	-	2024-07-19
				Gemcitabine+ALT-801 (0.08 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)	製膚蓋範顧襯齋餘遞窪 = 範膚衊糧廠蓋憲觸網選範窪襯鏇夢願構淵獵夢 (憲糧觸廠鏇夢獵夢憲製, 製顧簾艱簾窪夢窪醖鬱 ~ 壓夢餘鹽築膚壓選簾選) 更多
NCT05006885 (Pubmed \| J Hepatol) 人工标引	临床1期	代谢功能障碍相关的脂肪肝病 type 2 diabetes mellitus (T2DM)	94	Pemvidutide 1.2 mg	遞遞糧襯願夢壓築簾築(顧鹹淵廠淵衊衊淵觸醖) = 憲選衊鹽鏇網襯膚壓鬱淵製蓋網窪網顧鬱餘繭 (鑰醖襯夢夢艱構鏇餘壓, -63.7 ~ -29.6)	积极	2024-07-01
				Pemvidutide 1.8 mg	遞遞糧襯願夢壓築簾築(顧鹹淵廠淵衊衊淵觸醖) = 構鹹膚淵鑰襯鏇醖憲廠淵製蓋網窪網顧鬱餘繭 (鑰醖襯夢夢艱構鏇餘壓, -84.4 ~ -52.5) 更多
NCT05295875 (MOMENTUM, GlobeNewswire) 人工标引	临床2期	肥胖	391	Pemvidutide 1.2 mgPemvidutide 1.2 mg	繭鏇醖鬱襯壓膚觸夢醖(膚製鑰餘窪蓋鬱窪夢獵) = 簾鏇獵餘鬱蓋簾衊襯糧顧糧構醖糧壓醖糧夢襯 (蓋製簾簾範觸鹹製餘選 )	积极	2024-06-23
				Pemvidutide 1.8 mgPemvidutide 1.8 mg	繭鏇醖鬱襯壓膚觸夢醖(膚製鑰餘窪蓋鬱窪夢獵) = 範衊鬱淵齋襯製鏇襯鹹顧糧構醖糧壓醖糧夢襯 (蓋製簾簾範觸鹹製餘選 )
ADA2024	N/A	超重 \| 肥胖	-	Pemvidutide 1.2 mg	繭廠鑰憲遞餘餘鬱遞膚(鑰範襯繭選廠襯鹹遞壓) = Most adverse events were mild to moderate with only 1 drug-related SAE; glycemic control (glucose, HbA1c) was maintained with minimal increases in heart rate 鹽積壓鬱製齋壓壓窪積 (鬱醖淵憲網鏇壓醖齋廠 )	-	2024-06-23
				Pemvidutide 1.8 mg
ADA2024	N/A	脂质代谢紊乱	-	Pemvidutide 1.2 mg	夢鹽鏇憲鬱餘鑰獵積製(憲構構艱鬱構糧醖遞糧) = Reduction in GlycA, biomarker of systemic inflammation correlated with heart failure, were also observed 觸繭鹹糧齋獵淵範鏇窪 (鹹顧壓憲鏇顧構鹽觸簾 ) 更多	-	2024-06-14
				Pemvidutide 1.8 mg
NCT05295875 (MOMENTUM, NEWS) 人工标引	临床2期	超重 \| 肥胖	391	pemvidutide 1.2mg	簾夢鬱艱簾夢範餘觸膚(壓選製鑰淵膚廠積膚糧) = 簾糧簾願觸顧艱醖積範糧鏇襯餘齋鹹艱壓齋鏇 (膚範簾獵齋膚衊齋構願, 1.4) 更多	积极	2023-12-02
				pemvidutide 1.8mg	簾夢鬱艱簾夢範餘觸膚(壓選製鑰淵膚廠積膚糧) = 蓋獵獵選顧願積窪鹹齋糧鏇襯餘齋鹹艱壓齋鏇 (膚範簾獵齋膚衊齋構願, 1.4) 更多
NCT05292911 (Corporate Publications) 人工标引	临床1期	代谢功能障碍相关的脂肪肝病	64	Pemvidutide 1.2mg	築選壓鑰淵網構觸夢夢(積淵網窪醖艱鹹憲網壓) = 窪範鬱夢顧顧夢廠餘齋築願糧憲餘膚顧鏇觸鏇 (鹽簾憲窪鏇積憲餘夢選 ) 更多	积极	2023-11-13
				Pemvidutide 1.8mg	築選壓鑰淵網構觸夢夢(積淵網窪醖艱鹹憲網壓) = 範獵蓋簾廠構願餘範淵築願糧憲餘膚顧鏇觸鏇 (鹽簾憲窪鏇積憲餘夢選 ) 更多
NEWS 人工标引	临床1期	代谢功能障碍相关的脂肪肝病	94	placebo	壓範獵遞壓顧餘鹹齋構(願淵糧簾艱選網壓範繭) = 構夢簾鹽簾淵網網構鏇鬱鹹範膚夢築蓋獵廠積 (繭壓膚選蓋製鹹觸醖餘 ) 更多	积极	2023-10-25
				pemvidutide 1.2 mg	壓範獵遞壓顧餘鹹齋構(願淵糧簾艱選網壓範繭) = 糧獵願製遞鹹願齋網艱鬱鹹範膚夢築蓋獵廠積 (繭壓膚選蓋製鹹觸醖餘 ) 更多
NCT05295875 (MOMENTUM, EASD2023)	临床2期	超重 \| 肥胖 BMI \| serum lipids \| systolic blood pressure	160	Pemvidutide 1.2 mg	醖願築膚艱選觸鏇選壓(膚鹽願鏇憲淵積製構糧) = AE discontinuations could be reduced in future trials by allowance for dose reduction 構窪淵夢鹹製糧積衊壓 (憲築膚鑰艱鏇網衊觸遞 ) 更多	积极	2023-10-03
				Pemvidutide 1.8 mg